Skip to main content
Top
Published in: Inflammation 3/2016

Open Access 01-06-2016 | ORIGINAL ARTICLE

Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis

Authors: Anna Lemańska-Perek, Dorota Krzyżanowska-Gołąb, Małgorzata Pupek, Piotr Klimeczek, Wojciech Witkiewicz, Iwona Kątnik-Prastowska

Published in: Inflammation | Issue 3/2016

Login to get access

Abstract

Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interplaying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin complexes were analyzed in 80 plasma samples of patients suspected of coronary artery disease based on clinical evaluation and changes in arteries found by computed tomographic coronary angiography. The study showed that in the plasma of the patients’ group with high risk of coronary artery disease EDA-FN concentration was significantly higher (3.5 ± 2.5 mg/L; P < 0.025) and the molecular FN-fibrin complexes of 1000 kDa and higher occurred more often than in the groups of patients with mild risk of coronary artery disease and the normal age-matched. The increased level of EDA-FN and occurrence of FN-fibrin complexes could have a potential diagnostic value in the diagnosis and management of patients with coronary artery disease.
Literature
1.
go back to reference Petersen, S., V. Peto, M. Rayner, J. Leal, R. Luengo-Fernandez, and A. Gray. 2005. European cardiovascular disease statistics. London: British Heart Foundation. Petersen, S., V. Peto, M. Rayner, J. Leal, R. Luengo-Fernandez, and A. Gray. 2005. European cardiovascular disease statistics. London: British Heart Foundation.
2.
go back to reference Hansson, G. 2005. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 16: 1685–95.CrossRef Hansson, G. 2005. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 16: 1685–95.CrossRef
5.
go back to reference Tabas, I., K.J. Williams, and J. Borén. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 16: 1832–44.CrossRef Tabas, I., K.J. Williams, and J. Borén. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 16: 1832–44.CrossRef
6.
go back to reference Didangelos, A., X. Yin, K. Mandal, M. Baumert, M. Jahangiri, and M. Mayr. 2010. Proteomics characterization of extracellular space components in the human aorta. Molecular & Cellular Proteomics 9: 2048–62.CrossRef Didangelos, A., X. Yin, K. Mandal, M. Baumert, M. Jahangiri, and M. Mayr. 2010. Proteomics characterization of extracellular space components in the human aorta. Molecular & Cellular Proteomics 9: 2048–62.CrossRef
7.
go back to reference Cromar, G.L., X. Xiong, E. Chautard, S. Ricard-Blum, and J. Parkinson. 2012. Toward a systems level view of the ECM and related proteins: A framework for the systematic definition and analysis of biological systems. Proteins 80: 1522–44.CrossRefPubMed Cromar, G.L., X. Xiong, E. Chautard, S. Ricard-Blum, and J. Parkinson. 2012. Toward a systems level view of the ECM and related proteins: A framework for the systematic definition and analysis of biological systems. Proteins 80: 1522–44.CrossRefPubMed
8.
go back to reference White, E.S., and A.F. Muro. 2011. Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 63: 538–46.CrossRefPubMed White, E.S., and A.F. Muro. 2011. Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 63: 538–46.CrossRefPubMed
9.
go back to reference To, W.S., and K.S. Midwood. 2011. Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogen Tissue Repair 4: 21.CrossRef To, W.S., and K.S. Midwood. 2011. Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogen Tissue Repair 4: 21.CrossRef
10.
go back to reference Schwarzbauer, J.E., and D.W. DeSimone. 2011. Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harbor Perspectives in Biology 96: 2588–2590. Schwarzbauer, J.E., and D.W. DeSimone. 2011. Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harbor Perspectives in Biology 96: 2588–2590.
11.
go back to reference Hynes, R.O. 1999. The dynamic dialogue between cells and matrices: Implications of fibronectin’s elasticity. Proceedings of the National Academy of Sciences USA 6: 2588–90.CrossRef Hynes, R.O. 1999. The dynamic dialogue between cells and matrices: Implications of fibronectin’s elasticity. Proceedings of the National Academy of Sciences USA 6: 2588–90.CrossRef
12.
13.
go back to reference Moretti, F.A., A.K. Chauhan, A. Iaconcig, F. Porro, F.E. Baralle, and A.F. Muro. 2007. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. The Journal of Biological Chemistry 282: 28057–62.CrossRefPubMed Moretti, F.A., A.K. Chauhan, A. Iaconcig, F. Porro, F.E. Baralle, and A.F. Muro. 2007. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. The Journal of Biological Chemistry 282: 28057–62.CrossRefPubMed
14.
go back to reference Kostourou, V., and V. Papalazarou. 2014. Non-collagenous ECM proteins in blood vessel morphogenesis and cancer. BBA 1840: 2403–13.PubMed Kostourou, V., and V. Papalazarou. 2014. Non-collagenous ECM proteins in blood vessel morphogenesis and cancer. BBA 1840: 2403–13.PubMed
15.
go back to reference Wang, Y., A. Reheman, C.M. Spring, J. Kalantari, A.H. Marshall, A.S. Wolberg, et al. 2014. Plasma fibronectin supports hemostasis and regulates thrombosis. The Journal of Clinical Investigation 10: 4281–93.CrossRef Wang, Y., A. Reheman, C.M. Spring, J. Kalantari, A.H. Marshall, A.S. Wolberg, et al. 2014. Plasma fibronectin supports hemostasis and regulates thrombosis. The Journal of Clinical Investigation 10: 4281–93.CrossRef
16.
17.
go back to reference Sakai, T., K.J. Johnson, M. Murozono, K. Sakai, M.A. Magnuson, T. Wieloch, et al. 2001. Plasma fibronectin support neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature Medicine 7: 324–30.CrossRefPubMed Sakai, T., K.J. Johnson, M. Murozono, K. Sakai, M.A. Magnuson, T. Wieloch, et al. 2001. Plasma fibronectin support neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature Medicine 7: 324–30.CrossRefPubMed
18.
go back to reference Tate, C.C., A.J. García, and M.C. LaPlaca. 2007. Plasma fibronectin is neuroprotective following traumatic brain injury. Experimental Neurology 1: 13–22.CrossRef Tate, C.C., A.J. García, and M.C. LaPlaca. 2007. Plasma fibronectin is neuroprotective following traumatic brain injury. Experimental Neurology 1: 13–22.CrossRef
19.
go back to reference Makogonenko, E., K.C. Ingham, and L. Medved. 2007. Interaction of the fibronectin COOH terminal fib-2 regions with fibrin: Further characterization and localization of the fib-2 binding sites. Biochemistry 8: 5418–26.CrossRef Makogonenko, E., K.C. Ingham, and L. Medved. 2007. Interaction of the fibronectin COOH terminal fib-2 regions with fibrin: Further characterization and localization of the fib-2 binding sites. Biochemistry 8: 5418–26.CrossRef
20.
go back to reference Ramanathan, A., and N. Karuri. 2014. Fibronectin alters the rate of formation and structure of the fibrin matrix. Biochemical and Biophysical Research Communications 443: 395–99.CrossRefPubMed Ramanathan, A., and N. Karuri. 2014. Fibronectin alters the rate of formation and structure of the fibrin matrix. Biochemical and Biophysical Research Communications 443: 395–99.CrossRefPubMed
21.
go back to reference Leiss, M., K. Beckmann, A. Giros, M. Costell, and R. Fassler. 2008. The role of integrin binding sites in fibronectin matrix assembly in vivo. Current Opinion in Cell Biology 20: 502–7.CrossRefPubMed Leiss, M., K. Beckmann, A. Giros, M. Costell, and R. Fassler. 2008. The role of integrin binding sites in fibronectin matrix assembly in vivo. Current Opinion in Cell Biology 20: 502–7.CrossRefPubMed
22.
go back to reference Khan, Z.A., B.M. Chan, S. Uniyal, Y.P. Barbin, H. Farhangkhoee, S. Chen, et al. 2005. EDB fibronectin and angiogenesis—A novel mechanistic pathway. Angiogenesis 8: 183–196.CrossRefPubMed Khan, Z.A., B.M. Chan, S. Uniyal, Y.P. Barbin, H. Farhangkhoee, S. Chen, et al. 2005. EDB fibronectin and angiogenesis—A novel mechanistic pathway. Angiogenesis 8: 183–196.CrossRefPubMed
23.
go back to reference Maurer, E., M. Schaff, N. Receveur, C. Bourdon, L. Mercier, B. Nieswandt, et al. 2015. Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. Thrombosis and Haemostasis 114: 1175–88.CrossRefPubMed Maurer, E., M. Schaff, N. Receveur, C. Bourdon, L. Mercier, B. Nieswandt, et al. 2015. Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. Thrombosis and Haemostasis 114: 1175–88.CrossRefPubMed
24.
go back to reference Cho, J., and D.F. Mosher. 2006. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 9: 3555–63.CrossRef Cho, J., and D.F. Mosher. 2006. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 9: 3555–63.CrossRef
25.
go back to reference Prakash, P., P.P. Kulkarni, S.R. Lentz, and A.K. Chauhan. 2015. Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. Blood 125: 3164–72.CrossRefPubMedPubMedCentral Prakash, P., P.P. Kulkarni, S.R. Lentz, and A.K. Chauhan. 2015. Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. Blood 125: 3164–72.CrossRefPubMedPubMedCentral
26.
go back to reference Rohwedder, I., E. Montanez, K. Beckmann, E. Bengtsson, P. Dunér, J. Nilsson, et al. 2012. Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Molecular Medicine 4: 564–76.CrossRefPubMedPubMedCentral Rohwedder, I., E. Montanez, K. Beckmann, E. Bengtsson, P. Dunér, J. Nilsson, et al. 2012. Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Molecular Medicine 4: 564–76.CrossRefPubMedPubMedCentral
27.
go back to reference Zhang, Y., X. Zhou, J.C. Krepinsky, C. Wang, J. Segbo, and F. Zheng. 2006. Association study between fibronectin and coronary heart disease. Clinical Chemistry and Laboratory Medicine 44: 37–42.CrossRefPubMed Zhang, Y., X. Zhou, J.C. Krepinsky, C. Wang, J. Segbo, and F. Zheng. 2006. Association study between fibronectin and coronary heart disease. Clinical Chemistry and Laboratory Medicine 44: 37–42.CrossRefPubMed
28.
go back to reference Ozcelik, F., O. Erdogan, M. Aktoz, G. Ekuklu, E. Tatli, and M. Demir. 2009. Diagnostic value of plasma fibronectin level in predicting the presence and severity of coronary artery disease. Annals of Hematology 88: 249–53.CrossRefPubMed Ozcelik, F., O. Erdogan, M. Aktoz, G. Ekuklu, E. Tatli, and M. Demir. 2009. Diagnostic value of plasma fibronectin level in predicting the presence and severity of coronary artery disease. Annals of Hematology 88: 249–53.CrossRefPubMed
30.
go back to reference van Keulen, J.K., D.P. de Kleijn, M.M. Nijhuis, E. Busser, E. Velema, R. Fijnheer, et al. 2007. Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis 195: 83–91.CrossRef van Keulen, J.K., D.P. de Kleijn, M.M. Nijhuis, E. Busser, E. Velema, R. Fijnheer, et al. 2007. Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis 195: 83–91.CrossRef
31.
go back to reference PulakazhiVenu, V.K., P. Uboldi, A. Dhyani, A. Patrini, R. Baetta, N. Ferri, et al. 2015. Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis 114: 186–97.CrossRef PulakazhiVenu, V.K., P. Uboldi, A. Dhyani, A. Patrini, R. Baetta, N. Ferri, et al. 2015. Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis 114: 186–97.CrossRef
32.
go back to reference Krzyżanowska-Gołąb, D., A. Lemańska-Perek, M. Pupek, K. Lindner, B. Polańska, I. Porębska, et al. 2014. Identification of soluble supramolecular FN-fibrin complexes in human plasma. Journal of Immunoassay and Immunochemistry 35: 412–27.CrossRefPubMed Krzyżanowska-Gołąb, D., A. Lemańska-Perek, M. Pupek, K. Lindner, B. Polańska, I. Porębska, et al. 2014. Identification of soluble supramolecular FN-fibrin complexes in human plasma. Journal of Immunoassay and Immunochemistry 35: 412–27.CrossRefPubMed
33.
go back to reference Lemańska-Perek, A., M. Pupek, B. Polańska, J. Leszek, and I. Kątnik-Prastowska. 2013. Alterations in molecular status of plasma fibronectin associated with aging of normal human individuals. Clinical Biochemistry 46: 787–94.CrossRefPubMed Lemańska-Perek, A., M. Pupek, B. Polańska, J. Leszek, and I. Kątnik-Prastowska. 2013. Alterations in molecular status of plasma fibronectin associated with aging of normal human individuals. Clinical Biochemistry 46: 787–94.CrossRefPubMed
34.
go back to reference Miszalski-Jamka, T., P. Klimeczek, R. Banyś, M. Krupiński, K. Nycz, K. Bury, et al. 2012. The composition and extent of coronary artery plaque detected by multislice computed tomographic angiography provides incremental prognostic value in patients with suspected coronary artery disease. International Journal of Cardiovascular Imaging 28: 621–31.CrossRefPubMed Miszalski-Jamka, T., P. Klimeczek, R. Banyś, M. Krupiński, K. Nycz, K. Bury, et al. 2012. The composition and extent of coronary artery plaque detected by multislice computed tomographic angiography provides incremental prognostic value in patients with suspected coronary artery disease. International Journal of Cardiovascular Imaging 28: 621–31.CrossRefPubMed
35.
go back to reference Pupek, M., D. Krzyżanowska-Gołąb, T. Dyła, A. Lemańska-Perek, R. Jankowska, and I. Kątnik-Prastowska. 2009. Presence of high-molecular-weight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer. Clinical Biochemistry 42: 654–61.CrossRefPubMed Pupek, M., D. Krzyżanowska-Gołąb, T. Dyła, A. Lemańska-Perek, R. Jankowska, and I. Kątnik-Prastowska. 2009. Presence of high-molecular-weight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer. Clinical Biochemistry 42: 654–61.CrossRefPubMed
36.
go back to reference Castellanos, M., R. Leira, J. Serena, M. Blanco, S. Pedraza, J. Castillo, et al. 2004. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35: 1671–76.CrossRefPubMed Castellanos, M., R. Leira, J. Serena, M. Blanco, S. Pedraza, J. Castillo, et al. 2004. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35: 1671–76.CrossRefPubMed
37.
go back to reference Kanters, S.D., J.D. Banga, A. Algra, R.C. Frijns, J.J. Beutler, and R. Fijnheer. 2001. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 24: 323–27.CrossRefPubMed Kanters, S.D., J.D. Banga, A. Algra, R.C. Frijns, J.J. Beutler, and R. Fijnheer. 2001. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 24: 323–27.CrossRefPubMed
38.
go back to reference von Au, A., M. Vasel, S. Kraft, C. Sens, N. Hackl, A. Marx, et al. 2013. Circulating fibronectin controls tumor growth. NeoPlasia 15: 925–38.CrossRef von Au, A., M. Vasel, S. Kraft, C. Sens, N. Hackl, A. Marx, et al. 2013. Circulating fibronectin controls tumor growth. NeoPlasia 15: 925–38.CrossRef
39.
go back to reference Chauhan, A.K., J. Kisucka, M.R. Cozzi, M.T. Walsh, F.A. Moretti, M. Battiston, et al. 2008. Prothrombotic effects of fibronectin isoforms containing the EDA domain. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 296–301.CrossRefPubMed Chauhan, A.K., J. Kisucka, M.R. Cozzi, M.T. Walsh, F.A. Moretti, M. Battiston, et al. 2008. Prothrombotic effects of fibronectin isoforms containing the EDA domain. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 296–301.CrossRefPubMed
40.
go back to reference Lemańska-Perek, A., B. Polańska, D. Krzyżanowska-Gołąb, and I. Kątnik-Prastowska. 2015. Occurrence of soluble supra-molecular FN-fibrin complexes in the plasma of children with recurrent respiratory infection. Annals of Clinical Biochemistry 4: 441–47.CrossRef Lemańska-Perek, A., B. Polańska, D. Krzyżanowska-Gołąb, and I. Kątnik-Prastowska. 2015. Occurrence of soluble supra-molecular FN-fibrin complexes in the plasma of children with recurrent respiratory infection. Annals of Clinical Biochemistry 4: 441–47.CrossRef
41.
go back to reference Pupek, M., R. Pawiłowicz, K. Lindner, D. Krzyżanowska-Gołąb, A. Lemańska-Perek, and B. Panaszek. 2016. Changes in plasma fibronectin molecular status in patients with multimorbidity due to the inflamm-aging phenomenon. Experimental Gerontology 77: 19–28.CrossRefPubMed Pupek, M., R. Pawiłowicz, K. Lindner, D. Krzyżanowska-Gołąb, A. Lemańska-Perek, and B. Panaszek. 2016. Changes in plasma fibronectin molecular status in patients with multimorbidity due to the inflamm-aging phenomenon. Experimental Gerontology 77: 19–28.CrossRefPubMed
42.
43.
44.
Metadata
Title
Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
Authors
Anna Lemańska-Perek
Dorota Krzyżanowska-Gołąb
Małgorzata Pupek
Piotr Klimeczek
Wojciech Witkiewicz
Iwona Kątnik-Prastowska
Publication date
01-06-2016
Publisher
Springer US
Published in
Inflammation / Issue 3/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0336-0

Other articles of this Issue 3/2016

Inflammation 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.